After 5 years of cooperation, the result of 2 tablet and film-coated tablet production lines achieving Japan-GMP certification in 2019 and 2020 has created a mark in the pharmaceutical industry, also showing that Taisho’s aspiration in committing to accompany DHG Pharma.
DHG Pharma currently has nearly 100 products manufactured on 2 lines and nearly 100 products reaching Japan-GMP thanks to the durable support from Taisho. DHG Pharma has just announced its business result in 2020 with a profit after tax of VND739 billion, increased by 17% compared to 2019. This is the highest net profit since the company listed on the stock exchange in 2006.
Compared with the plan assigned by shareholders, in the difficult market situation due to the COVID 19 pandemic, DHG Pharma has completed 97% in revenue and exceeding 14% in profit. By the end of 2020, the company keeps its position as the largest pharmaceutical company with its revenue equal to two behind combined competitors and its profitability outstripping the market average.
DHG Pharma said that last year its revenue from self-manufactured products increased and the company focused on selling main products with Japan-GMP standard in cooperation with Taisho.
As from listed in “Top 10 outstanding M&A deals in 2018-2019” voted by Vietnam Investment Review, the story “Taisho - DHG Pharma” has always been interested by consumers. Officially, a strategic cooperation was from 2016, Taisho has committed to enhancing competitive capacity in domestic and foreign markets of DHG Pharma as well as supporting factory improvement to global standard and products with international quality.
Experts at that time said that, this commitment was estimated to take 8 to 10 years to come true, to be able to confirm two enterprises having good companionship and how far they go. However, after only 5 years, a series of achievements have told for all about a sustainable future of both sides. In particular, the biggest achievement is that Taisho has successfully supported DHG Pharma to deploy 2 production lines of tablets and film-coated tablets meeting Japan-GMP standard.
Taking about Japan-GMP, this is the highest drug quality standard from Japan Pharmaceutical and Medical Devices Agency (PMDA). With many and many strict technical barriers, Japan-GMP is prioritized for bidding into high-value drugs in hospital channel in Vietnam, easily applying for visas to Japan, Europe, etc. Therefore, 2 years and 2 Japan-GMP lines can be said to have made a mark in pharmaceutical industry as well as demonstrated Taisho’s commitment in strong companionship to Vietnamese people, helping drug consumers benefit greatly in quality and price.
